MediWound (MDWD) Q1 FY26 earnings call

MediWound continues to advance its EscharEx Phase III VALUE study and expand NexoBrid's commercial footprint, despite a temporary slowdown in EscharEx enrollment due to operational factors now being addressed. The company secured a significant BARDA contract for NexoBrid and is preparing its expanded manufacturing facility, reaffirming full-year revenue guidance based on expected second-half government-related revenue.